Reference : CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/10993/54416
CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells
English
Reigstad, Agathe [University of Bergen - UiB > Department of Biomedicine]
Herdlevær, Christina Frantzen [University of Bergen - UiB > Department of Biomedicine]
Rigg, Emma [University of Bergen - UiB > Department of Biomedicine]
Hoang, Tuyen [University of Bergen - UiB > Department of Biomedicine]
Bjørnstad, Ole Vidhammer [University of Bergen - UiB > Department of Biomedicine]
Aasen, Synnøve Nymark [University og Bergen - UiB > Department of Biomedicine > > ; Western Norway University of Applied Sciences > Faculty of Health and Social Sciences]
Preis, Jasmin Renate mailto [University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM) >]
Haan, Claude mailto [University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM) >]
Sundstrøm, Terje [HaukelHaukeland University Hospital > Department of Neurosurgery > > ; University of Bergen - UiB > Department of Clinical Medicine]
Thorsen, Frits [University of Bergen - UiB > Department of Biomedicine > > ; University of Bergen - UiB > Department of Biomedicine > Molecular Imaging Center]
9-Sep-2022
PLoS ONE
Public Library of Science
Yes
1932-6203
San Franscisco
United States - California
[en] Melanomas frequently metastasize to the brain. Despite recent progress in the treatment of
melanoma brain metastasis, therapy resistance and relapse of disease remain unsolved
challenges. CCT196969 is a SRC family kinase (SFK) and Raf proto-oncogene, serine/thre onine kinase (RAF) inhibitor with documented effects in primary melanoma cell lines in vitro
and in vivo. Using in vitro cell line assays, we studied the effects of CCT196969 in multiple
melanoma brain metastasis cell lines. The drug effectively inhibited proliferation, migration,
and survival in all examined cell lines, with viability IC50 doses in the range of 0.18–2.6 μM.
Western blot analysis showed decreased expression of p-ERK, p-MEK, p-STAT3 and
STAT3 upon CCT196969 treatment. Furthermore, CCT196969 inhibited viability in two B Raf Proto-Oncogene (BRAF) inhibitor resistant metastatic melanoma cell lines. Further in
vivo studies should be performed to determine the treatment potential of CCT196969 in
patients with treatment-naïve and resistant melanoma brain metastasis.
http://hdl.handle.net/10993/54416
10.1371/journal.pone.0273711
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0273711

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Registad, Preis, et al. CCT inh growth of melanoma brain metastasis. PLOS 2022.pdfPublisher postprint2.59 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.